Advertisement

Early Doses of Warfarin Paradoxically Associated with Higher Stroke Risk — Physician’s First Watch

Medical News |
December 19, 2013

Early Doses of Warfarin Paradoxically Associated with Higher Stroke Risk

By Joe Elia

Patients with atrial fibrillation seem to be at increased risk for ischemic stroke when starting warfarin prophylaxis, according to a case-control study in the European Heart Journal.

The study was undertaken after trials of both apixaban and rivaroxaban noted increased stroke risks among patients transitioning to open-label warfarin. This study was funded by the makers of apixaban.

Using a U.K. database, researchers examined a cohort of some 70,000 patients with AF; they matched 5500 cases of ischemic stroke with 55,000 controls. AF patients initiating warfarin therapy had a 71% increased risk for ischemic stroke within the first 30 days of therapy, compared with those on no anticoagulants. The risk was highest in the first week. However, the warfarin group had half the stroke risk after 30 days.

The authors say the observed "paradoxical procoagulant effect" may be due to warfarin's effect in blocking some endogenous anticoagulants.

Reader Comments (3)

AHMED SABRY Physician, Cardiology

first, I would like to thank this site for the service presenting. and if possible expand the free material for learning purposes

ALI MADI Physician, Internal Medicine, TMC/TRIPOLI

Is this paradoxical procoagulant effect noted in warfarin treatment of pulmonary embolism

ALI MADI

this paradoxical procoagulant effect is not observed DVT/PE

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement